US imposes 100% tariff on imported patented pharmaceuticals, impacting Australian exporters like CSL
Consensus Summary
Donald Trump imposed a 100% tariff on patented pharmaceuticals imported into the US, effective July 31, 2025, targeting Australia’s $1.3–2 billion annual drug exports. The move aims to reshoring production under Section 232 of US trade law, avoiding Supreme Court invalidation of earlier tariffs. Australia’s largest exporter, CSL, faces potential exemptions for its US-manufactured plasma therapies or reduced tariffs if it expands domestic production further. The Albanese government and opposition have pledged to fight for exemptions, but Health Minister Mark Butler firmly rejected negotiations on Australia’s Pharmaceutical Benefits Scheme (PBS), which ensures lower drug prices for Australians. Other countries like the EU, Japan, and the UK secured lower tariffs (10–15%) through trade deals, while smaller firms get 180 days to comply. Critics warn the tariffs could disrupt global supply chains and deter pharmaceutical innovation, as companies may delay launching new drugs in Australia due to pricing pressures from US demands. CSL’s ongoing $1.5–2.2 billion US expansion reflects preemptive efforts to mitigate the tariff impact, though exemptions remain uncertain.
✓ Verified by 2+ sources
Key details reported by multiple sources:
- Donald Trump signed an executive order imposing a 100% tariff on patented pharmaceuticals manufactured outside the US, effective July 31, 2025 (SMH, THEAGE, NEWSCOMAU, GUARDIAN, ABC).
- Australia exported approximately $US1.32–$US2 billion worth of pharmaceuticals to the US in 2024–2025 (NEWSCOMAU, ABC, GUARDIAN).
- CSL (ASX-listed biotech firm) is Australia’s largest pharmaceutical exporter to the US, with manufacturing plants in the US, Australia, and Europe (SMH, THEAGE, NEWSCOMAU, GUARDIAN, ABC).
- CSL’s US-based plasma-derived therapies (majority of its US exports) may be exempt from tariffs if they meet an ‘urgent US health need’ or if Australia negotiates a trade deal (SMH, THEAGE, NEWSCOMAU, ABC).
- Companies moving production to the US can reduce tariffs to 20% (or zero if granting ‘most favoured nation’ drug pricing status), with 120 days for large firms and 180 days for smaller ones (SMH, THEAGE, NEWSCOMAU, GUARDIAN, ABC).
- Japan, EU, South Korea, Switzerland, and Liechtenstein received 15% tariffs; the UK secured a 10% rate (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- Australia’s Pharmaceutical Benefits Scheme (PBS) is not negotiable, with Health Minister Mark Butler stating ‘no way we’re negotiating about those fundamental elements’ (SMH, THEAGE, NEWSCOMAU, GUARDIAN, ABC).
- CSL announced a $US1.5–$US2.2 billion expansion of its US manufacturing facility in Kankakee, Illinois, set to complete by 2031 (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
- The tariffs apply only to patented drugs, not generic medicines (NEWSCOMAU, ABC).
- The tariffs are enacted under Section 232 of the Trade Expansion Act (not presidential emergency powers), avoiding Supreme Court invalidation (SMH, THEAGE, ABC).
- Opposition Leader Angus Taylor (Coalition) stated the government and opposition would ‘work to get it overturned or get an exemption for Australian exporters’ (SMH, THEAGE, NEWSCOMAU, ABC).
- Trump’s tariffs were timed to mark one year since his ‘Liberation Day’ tariffs (February 2025), which were later struck down by the Supreme Court (SMH, THEAGE, ABC).
Points of Difference
Details reported by only one source:
- White House official explicitly stated ‘Australia does not have a special pharma tariff rate’ (SMH only).
- Trump’s executive order adjusts steel tariffs: 0% for products with <15% steel content, 25% for >15% (SMH only).
- US Commerce Department has discretion to grant exemptions to companies like CSL (SMH only).
- Trump’s trade tsar Jamieson Greer mentioned the order was focused on ‘deals that had already been made’ with companies in Australia, Austria, and France (SMH only).
- Medicines Australia spokesperson noted ‘significant scrutiny over new medicines launches’ due to low Australian PBS prices, citing delays in new drugs entering Australia (NEWSCOMAU only).
- CSL’s plasma-derived therapies are used to treat ‘rare autoimmune diseases and blood-clotting disorders’ (NEWSCOMAU only).
- Communications Minister Anika Wells stated the Australian PBS is ‘world leading’ and ‘not for sale’ (GUARDIAN only).
- Guardian cited a CSL spokesperson saying ‘we do not anticipate material impact’ from tariffs due to US-sourced plasma (GUARDIAN only).
- Senior administration official claimed ‘too many drugs driven by US R&D are now produced abroad,’ making the US ‘beholden to these other countries’ (ABC only).
- ABC reported Trump previously suggested the tariff could be as high as 200% (ABC only).
- ABC noted CSL’s social media post in September 2024 stating it ‘does not expect any material impact’ from the tariff (ABC only).
- ABC clarified the tariffs are under ‘national security’ trade law, unaffected by Supreme Court ruling (ABC only).
- SBS headline quotes Health Minister Mark Butler calling the decision ‘deeply disappointing and deeply concerning’ (SBS only).
Contradictions
Conflicting information between sources:
- The Guardian and ABC report CSL’s US plasma-derived therapies are exempt due to US-sourced plasma, while SMH and THEAGE emphasize exemptions depend on trade deals or health needs—implying ambiguity in eligibility.
- NEWSCOMAU states Australia exported $US1.32bn in 2025, but ABC and GUARDIAN cite $US1.3–$US2bn for 2024–2025 (potential data discrepancy).
- SMH and THEAGE mention a 20% tariff for companies moving production to the US, but ABC clarifies this is contingent on ‘striking deals to lower US prices’—implying additional conditions.
- NEWSCOMAU reports the tariff applies to ‘patented products, not generic medicines,’ while SMH and THEAGE do not specify this distinction explicitly.
- ABC states Trump previously suggested a 200% tariff, but all other sources confirm the final rate is 100% (SMH, THEAGE, NEWSCOMAU, GUARDIAN).
Source Articles
Breaking: Trump puts 100pc tariff on some pharmaceuticals
The US president's latest order shows he remains committed to his aggressive tariff regime despite February's Supreme Court ruling that invalidated his centrepiece "liberation day" tariffs....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....
Trump slaps huge tariff on medicines
US President Donald Trump has followed through on another tariff threat, putting a 100 per cent levy on a major Australian export....
Australia says it won’t raise drug prices after Trump’s 100% tariff on pharmaceuticals imported into US
Health minister Mark Butler says federal government is ‘not negotiating’ when it comes to removing price protections on common medications Get our breaking news email , free app or daily news podcast ...
What Trump's 100 per cent pharmaceutical tariff means for Australia
Australia exported nearly two billion dollars worth of pharmaceuticals to the US last year....
Trump imposes 100 per cent tariff on Australian drugs – but with caveats
Australia’s largest biotech firm, CSL, could be exempt from the new tariffs, which will not apply to therapies derived from blood plasma in certain circumstances....